Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine | The Manila Times
No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported
Ähnliche Seiten
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial | The Manila Times
https://www.manilatimes.net/2026/06/25/tmt-newswire/globenewswire/vaxart-announces-update-to-barda-funding-award-to-reflect-current-scope-of-covid-19-oral-pill-vaccine-trial/2372795Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine | The Manila Times
https://www.manilatimes.net/2026/06/16/tmt-newswire/globenewswire/invivyd-announces-completion-of-enrollment-in-phase-3-liberty-trial-evaluating-vyd2311-antibody-versus-mrna-covid-19-vaccine/2366391
First oral drug to prevent COVID after exposure clears Phase III trial
https://refractor.io/infectious-diseases/fda-approves-covid-19-ensitrelvir/uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy | The Manila Times
https://www.manilatimes.net/2026/06/19/tmt-newswire/globenewswire/uniqure-announces-preliminary-data-on-the-first-cohort-in-the-phase-iiia-clinical-trial-of-amt-260-in-refractory-mesial-temporal-lobe-epilepsy/2369032
uniQure Inc.: uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
https://www.finanznachrichten.de/nachrichten-2026-06/68814137-uniqure-inc-uniqure-announces-preliminary-data-on-the-first-cohort-in-the-phase-i-iia-clinical-trial-of-amt-260-in-refractory-mesial-temporal-lobe-e-399.htm